Business Wire

IQM-QUANTUM-COMPUTERS

21.12.2021 12:02:08 CET | Business Wire | Press release

Share
IQM Continues Its European Expansion; New French Subsidiary Will Focus on IQM’s Co-design Customers in Aviation, Space, and Cybersecurity.

IQM France will collaborate closely with customers in the aviation, space, and cybersecurity verticals using IQM’s co-design approach. IQM is also part of Atos’s Scaler program, and this subsidiary will focus further on HPC integration and offer quantum accelerators to supercomputing centers worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005096/en/

Through this new subsidiary, IQM joins the French quantum ecosystem that consists of world-renowned universities and research institutes and a fast-growing start-up scene and provides excellent industry infrastructure. IQM’s expertise and reach, combined with this vibrant ecosystem, will create significant opportunities for partnerships and collaboration in Europe and across the globe.

In the first phase, IQM France aims to tap into the extended talent pool of quantum students, postdocs, and experienced professionals. The plan is to start with a core team of business developers, products managers, quantum scientists, and engineers in 2022. The aim is to create a center of excellence in specific industry verticals and systematically grow in subsequent years.

IQM France’s office will be in the central hub at Spaces Les Halles on 40 rue du Louvre, Paris. Dr. Björn Pötter will take on the role of Country Manager for France in addition to his role as Global Head of Products at IQM. Dr. Pötter, who recently joined IQM, holds a PhD in physics and has extensive experience with digital technologies in the Aerospace and Cybersecurity industries. Dr. Pötter has held several international leadership positions with a focus on technology and innovation, among others at Airbus.

“I am excited to see IQM start its French operations in the Paris region, where I have been working for several years. The Paris team will build the bridge between the various IQM teams around Europe and the high-quality French quantum ecosystem. The team will enable local operations for collaborative IQM projects in strategic industrial areas,” said Dr. Pötter.

Speaking about this announcement, Dr. Jan Goetz, CEO and cofounder of IQM, said, “France plays an integral role in the quantum scientific research and has been on our roadmap for a while. I’m extremely pleased to announce the operations of our French entity today, especially at a time when the French quantum plan is gaining momentum. This French subsidiary together with our co-design teams in Bilbao and Munich and the quantum hardware and software teams in Espoo, Finland, will strengthen European quantum leadership.”

“The Paris region is proud to welcome a major European quantum computing player to the epicenter of the French quantum ecosystem. We support IQM’s local setup and growth to help them make the most of the excellent research and talent available. We are also convinced that IQM will thrive in France’s #1 aerospace region,” said Alexandra Dublanche, President of Choose Paris Region and Vice President in charge of Recovery, Attractiveness, Economic Development, and Innovation of the Paris Region.

“We are very thankful to Choose Paris Region and also Business France for the active, pragmatic, and timely support, which allowed us to set up IQM France in a very short time,” Dr. Pötter added.

In March 2021, Dr. Goetz presented on deep tech and building global tech leaders’ topics at the Scale-Up Europe event, where President Emmanuel Macron was an attendee. This presentation was part of the Scale-up Europe initiative facilitated by Sifted.

About IQM Quantum Computers:

IQM is a Pan-European leader in quantum computers.

IQM provides on-site quantum computing for research labs and supercomputing data centers and offers full access to its hardware. For industrial customers, IQM delivers the quantum advantage through a unique application-specific co-design approach.

IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is building a quantum computer in Germany that will be integrated into an HPC supercomputer to create an accelerator for future scientific research. IQM has offices in Bilbao, Munich, and Espoo and employs over 130 people. More information: www.meetiqm.com

Links to the quoted press releases:

  • IQM opens its exclusive quantum fabrication facility in Finland
  • IQM has delivered the first milestone of the Finnish quantum computer co-innovation project with VTT; the 5-qubit quantum computer is now operational.
  • IQM, as part of the Q-Exa consortium , is building a quantum computer in Germany that will be integrated into an HPC supercomputer for the first time.

Registered office:

IQM Finland Oy, Keilaranta 19, 02150 Espoo, Finland

Choose Paris Region is the agency in charge of promoting the attractiveness of the Paris region in terms of international business. The agency works in partnership with all the region’s key players to create an appealing and coherent territorial offer, ensure promotion of the region, and offer a tailor-made service to support international businesses and professionals in their expansion.

https://www.chooseparisregion.org/

Headquarters:

Choose Paris Region, 18 rue de Londres, 75009 Paris

contact@chooseparisregion.org - +33 800 019 011

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye